Endothelial stem cell therapy - CellProThera

Drug Profile

Endothelial stem cell therapy - CellProThera

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CellProthera
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Endothelial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myocardial infarction

Most Recent Events

  • 15 Sep 2014 Preclinical trials in Myocardial infarction in France (Intramyocardial)
  • 15 Sep 2014 CellProThera plans a phase I/IIb trial for Myocardial infarction in United Kingdom and France
  • 06 Mar 2014 Protheracytes® receives Advanced Therapy Medicinal Product designation from the EMA for Myocardial infarction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top